In the Past 30 Days...
PER WEEK
PER POST
PER POST
In the last 30 days, the average company in this landscape has grown their audience by 0.1%. Gilead Sciences grew faster than everyone else, with 1.0% growth! On average, each post in this landscape earns more than 515.8 engagements. Abbott is topping the charts with more than 4.75k engagements per post on their 23 posts in the last 30 days.
317 Likes • 0 Comments
After learning she was living with #HIV in 2009, Toi, a #ChooseU ambassador, navigated her diagnosis and treatment journey largely on her own. Inspired by her own story, Toi founded The Trans Women of Color Healing Project to improve the quality of life for individuals in the trans and gender-diverse community. Visit the link in our …
211 Likes • 0 Comments
Welcome to Inside the Archives. To celebrate 30 years as Novartis, we're opening the doors to our company archives, revealing 250 years of artifacts and anecdotes that have shaped who we are today. First up: the dyes that sparked a journey of innovation, from our earliest beginnings to the breakthroughs still ahead. It’s a powerful reminder that …
200 Likes • 8 Comments
Almost 50,000 donors and 150,000 lives saved, and we’re just getting started.🩸 Wisconsin and Nebraska hold the top spots in the We Give Blood competition for now, but with two months still left in the competition, there's still time to help your team climb the leaderboard. Give blood at any blood drive or center, and submit your …
155 Likes • 1 Comments
A breast cancer diagnosis can change everything in an instant. For more than 35 years, Novartis has been driving innovation in breast cancer, aiming to transform care and extend lives. This Breast Cancer Awareness Month, we're celebrating the progress made and reaffirming our commitment to our goal of helping more people move beyond a breast cancer diagnosis …
136 Likes • 4 Comments
To identify potential cancer treatments, scientists first must investigate how molecules behave and interact with the body at the molecular level. Next up in #WhatsInMyLab, Xiaoxiao, a senior principal scientist here at Pfizer, walks you through how her lab analyzes cellular proteomics to better understand the biological effects of potential cancer therapies. #Proteomics #Oncology #Science #Research #Innovation #Healthcare
20 Reactions • 36 Comments • 1 Shares
Check out this week's Extra Extra Big Deals! Use your ExtraCare card to get these deals September 27 to October 10, online and in store.
37 Reactions • 1 Comments • 4 Shares
Almost 50,000 donors and 150,000 lives saved, and we’re just getting started.🩸 Wisconsin and Nebraska hold the top spots in the We Give Blood competition for now, but with two months still left in the competition, there's still time to help your team climb the leaderboard. Give blood at any blood drive or center, and submit your …
27 Reactions • 2 Comments • 1 Shares
Behind every CAR-T cell therapy is a coordinated effort—teams working across time zones, critical logistics in motion and each patient's own cells processed with precision to create their individualized treatment for multiple myeloma. Take a behind-the-scenes look at how we turn this complexity into care and meet the people and systems making it possible: https://social.jnj.com/4xLDhL7
19 Reactions • 7 Comments • 0 Shares
October marks American Pharmacists Month. To our pharmacists: thank you for all you do for our patients and communities. Help us celebrate them by sharing a kind word in the comments.
20 Reactions • 2 Comments • 1 Shares
For 35 years, the Johnson & Johnson Institute has been training surgeons and healthcare providers (HCPs) to master cutting-edge surgical tools and technologies. Today, with 24 facilities worldwide, we’re meeting HCPs through key approaches like convenient online learning programs, in-person surgical training for early-career residents and partnerships with leading research centers. Read about how we’re shaping the …
21 Likes • 1 Retweets
Weak circulating tumor DNA (ctDNA) signals remain a primary bottleneck in minimal residual disease research. Roche’s sequencing by expansion (SBX) achieves the throughput necessary to bypass standard resolution limits. Discover more: go.roche.com/xsbxgen2 (Research use only) pic.x.com/Ve3P0HUh0B
12 Likes • 1 Retweets
#MEDIA – We are pleased that the New England Journal of Medicine has published phase III data demonstrating significant progression-free survival benefit with our investigational medicine for people with ER-positive advanced #BreastCancer. Read more pic.x.com/9atIAGAaFo
12 Likes • 1 Retweets
#MEDIA – We are pleased that the U.S. FDA has accepted the new drug application for our investigational medicine for both relapsing and primary progressive multiple sclerosis. Read here 👉 spkl.io/60187p5Iw #multiplesclerosis #MS pic.x.com/aXo7vfTl1W
12 Likes • 2 Retweets
#MEDIA: The U.S. FDA approved an expanded indication for our first-in-class treatment for adults and certain pediatric patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). bit.ly/4e53nkY pic.x.com/1dsTdmgsgd
10 Likes • 1 Retweets
To move retinal care forward, we must understand how solutions perform in everyday practice. As @EURETINA 2026 continues, Nilesh Mehta, Therapeutic Area Head, Ophthalmology at Roche, is sharing what our latest real-world evidence could mean for patients with neovascular pic.x.com/A9JIJHlmoK
The Social Media Benchmark Report
Ready to see how you stack up to your industry’s top social performers? Review the latest metrics on channels, engagement, post types, and more.